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Abstract: Background: Given the increasing request for natural pharmacological molecules, this study
assessed the antimicrobial capacity of Pistacia lentiscus L. essential oil (PLL-EO) obtained from the
leaves of wild plants growing in North Sardinia (Italy) toward a wide range of periodontal bacteria
and Candida, including laboratory and clinical isolates sp., together with its anti-inflammatory activity
and safety. Methods: PLL-EO was screened by gas chromatography/mass spectrometry. The minimal
inhibitory concentration (MIC) was determined. The anti-inflammatory activity was measured
by cyclooxygenase (COX-1/2) and lipoxygenase (LOX) inhibition, while the antioxidant capacity
was determined electro-chemically and by the MTT assay. The WST-1 assay was used to ascertain
cytotoxicity toward four lines of oral cells. Results: According to the concentrations of terpens, PLL-EO
is a pharmacologically-active phytocomplex. MICs against periodontal bacteria ranged between 3.13
and 12.5 µg/ml, while against Candida sp. they were between 6.25 and 12.5 µg/mL. Oxidation by
COX-1/2 and LOX was inhibited by 80% and 20% µg/mL of the oil, respectively. Antioxidant activity
seemed negligible, and no cytotoxicity arose. Conclusions: PLL-EO exhibits a broad-spectrum activity
against periodontal bacteria and Candida, with an interesting dual inhibitory capacity toward COX-2
and LOX inflammatory enzymes, and without side effects against oral cells.
Antibiotics 2020, 9, 281; doi:10.3390/antibiotics9060281 www.mdpi.com/journal/antibiotics
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1. Introduction
Periodontal and peri-implant diseases, in addition to Candida spp. infections, are among the
most common and recalcitrant oral plights that evoke immuno-inflammatory responses. Evidence is
provided that periodontitis is associated with an imbalance of the oral microbiome [1] and other risk
factors such as smoking, hyperglycaemia, and xerostomia [2,3]. Within the oral microbiome imbalance,
Gram-negative, proteolytic, and anaerobic biofilm-forming bacteria, namely Porphyromonas gingivalis,
Tannerella forsythia, and Fusobacterium nucleatum, may become dominant, settle gingival margins, and
pave the way for chronic multifactorial disease [1,4,5], whereas Candidiasis by Candida albicans and
Candida glabrata turns out to be among the predominant infective-agents in immunocompromised
patients [6]. Following epithelial cell harming by pathogenic agents, the inflammatory process
sets off, and pro-inflammatory cytokines are released to start the healing process [1,7,8]. However,
under these physio-pathological conditions, severe and recurrent inflammation can be concomitant
with periodontitis and oral Candidiasis [9,10], and may contribute to deleterious consequences.
Lasting oxidation of arachidonic acid by cyclooxygenases (COX-1 and COX-2) and lipoxygenase
(5-LOX) leads to the accumulation of prostaglandins and leukotrienes [11,12]. Among these oxidized
products, prostaglandine E2 (PGE2) and related lipid mediators activate immune cells and stimulate
pro-inflammatory and pro-coagulant responses. Furthermore, the activation of phagocytes within the
inflammation process burst oxygen consumption, jeopardizing severely cell redox homeostasis by
rising reactive oxygen species (ROS) [13]. Within this framework, the repair of the infected tissue is
hindered, favouring the outbreak of chronic multifactorial diseases [14–17].
With the intent to antagonise recurrent oral inflammation, oral antiseptics are often administered.
However, several synthetic molecules, such as chlorhexidine digluconate, largely used in commercial
oral antiseptics, have shown high cytotoxicity against human fibroblasts and osteoblasts [18–21].
Time-dependent toxicity was demonstrated in fibroblasts viability after exposure to chlorhexidine
>0.001% [19], and cellular damages were raised by the presence of other chemicals in the mixture
attesting an increase in toxicity by synthetic substances [21]. On the other hand, if employing systemic
non-steroidal anti-inflammatory drugs (NSAIDs) or even steroids, gastrointestinal and cardiac toxicity
as well as nephrotoxic side effects can occur [22–24].
Thus, new pharmacological molecules differently acting, with a broad-microbial targeting activity,
and able to constraint also the inflammation process without producing side effects to the host,
are needed [25]. In this regard, plant essential oils (EO) are potential candidates, even though, according
to concentration, toxicity towards cells has been reported [13,26]. Essential oils are phytocomplexes
composed of several chemical classes, among which polyphenols are acquiring an increasing interest
due to their functional properties [27–32]. Concerning these phytocomplexes, Pistacia lentiscus L.
(PLL), belonging to the Anacardiaceae family, is a wild-growing species of the Mediterranean basin
particularly diffused in Sardinia (Italy), with leaf-EO rich in terpenoids [33]. In popular medicine,
PLL plant and processed products (leaf-EO, drupe oil, resin) have been largely employed as oral
antiseptic, anti-inflammatory, analgesic, and healing agents [33,34]. Quartu et al. (2012) [35] reported
that PPL-leaf-EO promoted the biosynthesis of highly polyunsaturated fatty acids in mice, lowered
the expression of COX-2, and protected brain tissue from ischemia, while Orrù et al. (2017) [36],
employing PPL-drupe oil, evidenced a selective growth inhibition towards some pathogenic bacteria
of the oral cavity.
Given the above considerations, after determining the major constituents of PLL leaf essential
oil (PLL-EO), the purpose of this study was to evaluate its capacity for some functional implications
regarding the periodontal disease and Candidiasis. With this intention, we assessed the inhibitory
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ability to PLL-EO to a wide range of microorganisms and clinical species involved in these infections,
in addition to its anti-inflammatory strength. Further, we tested potential cytotoxicity of PLL-EO
against the periodontal ligament fibroblasts (PDLF), gingival fibroblasts (GF), gingival keratinocytes
(GK), and dysplastic oral keratinocytes (DOK).
The hypothesis of the present study was that PLL-EO has anti-microbial and anti-inflammatory
activities without negatively interfering with human cells viability.
2. Results
2.1. Essential Oil Yield and Chemical Fingerprinting
Following hydro-distillation, the yield of PLL-EO was about 0.41% (w/w). The GC-MS analyses
identified 64 constituents, which represented 97.28% of the total components (Table 1). Among these,
17 components made up 1% of the total. GC-MS identified α-pinene and terpinen-4-ol as the main
constituents of PLL-EO with a concentration of 16.89% and 16.49%, respectively. The monoterpenes,
limonene and β-myrcene, represented 3.89% and 0.87%, respectively, while the sesquiterpenes,
(Z)-caryophyllene, and (E)-caryophyllene, embodied 1.39% and 0.07%, respectively.
Table 1. Chemical composition of Pistacia lentiscus L. essential oil from fresh leaves.
RI apol Sper RI apol Lett Constituents % ID *
924 927 tricyclene 0.24 ± 0.01 MS-RI
930 931 α-thujene 0.23 ± 0.01 Std
939 937 α-pinene 16.89 ± 0.15 Std
955 956 camphene 1.04 ± 0.04 Std
977 975 sabinene 7.73 ± 0.11 Std
981 979 β-pinene 4.30 ± 0.05 Std
992 991 β-myrcene 0.87 ± 0.02 Std
1005 1003 α-phellandrene 7.39 ± 0.12 Std
1015 1017 α-terpinene 4.79 ± 0.04 Std
1025 1025 p-cymene 1.10 ± 0.03 Std
1027 1029 limonene 3.89 ± 0.07 Std
1031 1030 β-phellandrene 4.71 ± 0.05 MS-RI
1035 1037 Cis-β-ocimene 0.24 ± 0.02 MS-RI
1056 1056 isoamyl isobutyrate 0.55 ± 0.02 MS-RI
1056 1056 2-methylbuthyl butanoate 0.18 ± 0.01 Std
1064 1060 γ-terpinene 6.30 ± 0.09 Std
1087 1089 terpinolene 3.25 ± 0.02 MS-RI
1090 1091 p-cymenene 0.12 ± 0.01 MS-RI
1094 1094 isopentyl isivalerate 0.13 ± 0.01 MS-RI
1108 1108 n-amyl isovalerate 0.04 ± 0.01 MS-RI
1115 1117 fenchol 0.11 ± 0.01 MS-RI
1147 1144 Cis-β-terpineol 0.13 ± 0.01 Std
1166 1169 borneol-endo 0.16 ± 0.01 Std
1181 1177 terpinen-4-ol 16.49 ± 0.18 MS-RI
1187 1189 α-terpineol 3.98 ± 0.07 MS-RI
1194 1199 γ-terpineol 0.07 ± 0.01 MS-RI
1242 1238 isopentyl hexanoate 0.24 ± 0.02 MS-RI
1247 1247 2-methylbuthyl hexanoate 0.17 ± 0.01 Std
1258 1253 piperitone 0.05 ± 0.01 Std
1294 1294 2-undecanone 0.85 ± 0.03 MS-RI
1355 1351 α-cubebene 0.05 ± 0.01 Std
1378 1377 α-copaene 0.24 ± 0.01 MS-RI
1380 1382 β-maaliene 0.33 ± 0.02 MS-RI
1407 1409 (Z)-caryophyllene 1.39 ± 0.06 MS-RI
1419 1419 (E)-caryophyllene 0.07 ± 0.01 Std
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RI apol Sper RI apol Lett Constituents % ID *
1457 1460 alloaromadendrene 0.14 ± 0.01 Std
1480 1480 γ-muurolene 0.57 ± 0.03 Std
1485 1485 α-amorfene 0.07 ± 0.01 MS-RI
1486 1485 germacrene D 2.73 ± 0.11 MS-RI
1497 1499 Cis-dihydro apofarnesal 0.14 ± 0.01 MS-RI
1502 1500 α-muurolene 0.53 ± 0.02 Std
1509 1506 β-bisabolene 0.19 ± 0.01 MS-RI
1521 1523 δ-cadinene 1.43 ± 0.04 MS-RI
1535 1535 Trans-cadina-1(2),4-diene 0.15 ± 0.01 Std
1539 1539 α-cadinene 0.07 ± 0.01 Std
1552 1552 Cis-muurol-5-en-4-β-ol 0.07 ± 0.01 Std
1535 1535 Trans-cadin-4-en-7-ol 0.31 ± 0.02 Std
1639 1640 epi-α-cadinol 1.22 ± 0.08 Std
1644 1646 α-muurolol 0.94 ± 0.04 Std
1648 1652 cedr-8(15)-en-9-α-ol 0.12 ± 0.01 Std
96.96
* ID = Identification methods: MS by comparison of the mass spectrum with those of the computer mass libraries
Adams (NIST 11) and by interpretation of the mass spectra fragmentations; RI by comparison of retention index
with those reported in literature; Std by comparison of the retention time and mass spectrum of available authentic
standards; MS identification of mass spectrum. No-polar column ZB-5. Data are the mean of three replicates.
2.2. Minimal Inhibitory Concentrations Against Oral Bacteria and Candida sp.
The MIC of PLL-EO (Table 2) against oral bacteria involved in periodontal diseases ranged
between 3.13 µg/mL (P. gingivalis, T. forsythia) and 12.5 µg/mL (S. gordonii). Regarding the effects on
Candida sp., the recorded values ranged from 6.25 µg/mL for C. glabrata strains to 12.5 µg/mL for
C. albicans ones.
Table 2. MIC (µg/mL) of Pistacia lenticus L. essential oil against oral microbiota.
Strain Origin MIC (µg/mL PLL-EO)
Streptococcus gordonii ATCC 10558 Laboratory 12.5
Actinomyces naeslundii ATCC 12104 Laboratory 3.13
Fusobacterium nucleatum ATCC 25586 Laboratory 6.25
Porphyromonas gingivalis ATCC 33277 Laboratory 3.13
P. gingivalis BeOR6 Clinical isolate 1.63
P. gingivalis BeOR14 Clinical isolate 1.63
Tannerella forsythia ATCC 43330 Laboratory 3.13
T. forsythia Be13237 Clinical isolate 1.63
T. forsythia Be13216 Clinical isolate 3.13
Candida albicans ATCC 76615 Laboratory 12.5
C. albicans BeT41 Clinical isolate 12.5
C. albicans BeT603 Clinical isolate 12.5
Candida glabrata DSM 6425 Laboratory 6.25
C. glabrata Be10183 Clinical isolate 6.25
C. glabrata Be184 Clinical isolate 6.25
MIC: Minimal Inhibition Concentration; PLL-EO: Pistacia lentiscus L. leaves essential oil. Growth control with
distilled water, always confirmed the growth of all the microbial strains in the absence of PLL-EO.
2.3. Anti-inflammatory Assays
2.3.1. COX-1/2 Inhibition
The anti-inflammatory activity, expressed as a percentage of COX-1/2 inhibition by increasing
concentrations of PLL-EO (1, 10, and 100 µg/mL), allowed us to establish the IC50 values. Compared to
the control sample (0 PLL-EO), where the COX-1/2 activity was considered equal to 100% (Figure 1),
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the IC50 values resulted as 10.3 ± 4.4 µg/mL and 6.1 ± 2.5 µg/mL for COX-1 and COX-2, respectively.
These values were only seven times higher than the IC50 values of the positive control ibuprofen
(1.3 ± 0.5 µg/mL for COX-1, 0.87 ± 0.39 µg/mL for COX-2). Thus, the inhibitory activity of PLL-EO
toward COX-2 was higher in comparison to that produced toward COX-1, similarly as it was
regarding ibuprofen.
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Figure 1. The anti-inflammatory effect of PLL-EO toward cyclooxygenase (COX-1 and COX-2) activity.
2.3.2. LOX Inhibition
The measured values were related to a control sample, which represented 100% enzyme activity,
i.e., uninhibited reaction. According to the data (Figure 2), the highest PLL-EO concentration employed
(100 µg/mL) did not reach the IC50 value since the activity was lowered by 30% compared to the control.
Thus, PLL-EO showed a weak inhibitory effect toward LOX activity. Phenidone (100 µg/mL) used as
positive control inhibited LOX activity by 63.4 ± 8.6%.Antibiotics 2020, 9, x FOR PEER REVIEW 6 of 16 
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Figure 2. The anti-inflammatory effect of PLL-EO toward soybean lipoxygenase (LOX) activity.
2.3.3. Electro-Chemical Determination of the Antioxidant Activity
According to previous studies, the redox potential of +500 mV is used to detect the antioxidant
capacity of phenolic compounds in vegetable matrices, while +800 mV potential is used to assess the
total phenolics content [37,38]. A low oxidation potential indicates a high reducing power since the
ionization potential is the main factor to determine the efficiency of antioxidants [39]. In Figure 3,
the voltammogram of PLL-EO was compared with that of α-tocopherol (green line), a well-known
antioxidant molecule. The red line indicates PLL-EO oxidation occurred at +550 mV, where it splits
the baseline (black line) with an oxidation peak of about +800 mV. Thus, the data suggests a poor
antioxidant activity of the hydro-distilled EO. Cyclic voltammetries of PLL-EO main components
further accredit this result: α-pinene and terpinen-4-ol split the baseline at +600 mV and +450 mV,
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with peaks at +720 mV and +750 mV respectively, while no redox peaks were observed regarding
α-phellandrene (Figures S1–S3 in Supplementary Material).
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Figure 3. Cyclic voltammetry of PLL-EO with a scanned potential range (Eapp) between −200 mV and
+800 mV vs Ag/AgCl reference electrode, in the absence (black line) and in the presence of 200 mg/mL
PLL-EO (red line), in comparison with 1 mM α-tocopherol (green line).
2.4. Viability Assay
The protective effects of PLL EO toward the oxidative stress affecting the GF were evaluated by
the MTT assay, testing different concentrations of the oil. The results showed a significant increase
in cell viability when GFs were treated with 10, 25, 50 and 75 µg/mL of PLL EO in comparison to
that observed in the control group and using the DMSO 0.1%. Differently, the cells subjected to the
oxidative stress evidenced a vitality drop of about 30% in comparison to the control, and when PLL EO
was administered before the oxidative stress, no beneficial effects occurred (Figure 4).
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Figure 4. Primary gingival fibroblasts viability relative to the sole growth medium (CTRL),
if supplemented with 0.1% DMSO or 100 µM H2O2 and when amended with PLL-EO − H2O2
and PLL-EO + H2O2. The separation of mean values (n = 4) and standard deviation were calculated
according to the Student-Newman-Keuls test at p ≤ 0.05.
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2.5. Cytotoxicity Assay
Cytotoxicity effects of increasing concentrations of PLL-EO were recorded for PDLF, GF, GK,
and DOK cell lines following a 24 h incubation. The data did not evidence significant differences
(p < 0.05) between PLL-EO treated cells and the control. Thus, according to the highest concentration
employed in this experiment, it is possible to claim that no toxicity in oral cell lines occurred up to
100 µg/mL of the oil (Figure 5).
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Figure 5. The effect of increasing concentrations of PLL-EO on the viability of human oral cells
following 24 h incubation. GF: gingival fibroblasts; PDLF: periodontal ligament fibroblasts; GK:
gingival keratinocytes, and DOK: dysplastic oral keratinocytes. Data (mean from six parallels in three
independent experiments ± S.D.) are expressed as the percentage of viability of untreated cells (=100%).
3. Discussion
New treatment options for infections and inflammation should target selectively the pathogens,
preventing their ability to form biofilms [40]. Further, they should modulate the host inflammatory
response in order to antagonize the accumulation of PGE2 and leukotrienes in chronic inflammatory
diseases [11,41]. Moreover, there is a demand for biocompatibility to prevent side effects on the host [21,25].
Natural products are a valuable source of biomolecules that in view of their chemical versatility, offer the
possibility to synthesize new drugs containing all of the above-mentioned capacities [14,27–32].
In the present study, we evaluated the peculiar character of PLL essential oil derived from the
leaves of wild plants growing in the North of Sardinia. The data demonstrated PLL-EO possesses
antimicrobial activity against the tested species in addition to anti-inflammatory properties and high
biocompatibility. The antimicrobial capacity was studied by the broth microdilution method, according
to the recommendations of EUCAST, in order to compare the data to published reports. Similarly,
an enzymatic cell-free in vitro assay using human recombinant COX enzymes and using soybean LOX
was carried out to evaluate the inhibitory activity against the most relevant inflammatory mediators [27].
The antioxidant activity was assessed using an electron-chemical method measuring this capacity as
the redox properties of the raw oil and the most represented compounds. The electron-chemical system
has been credited as a very good device in such a field thanks to the high sensitivity, chemical inertness,
and versatility [37–39,42]. In addition, the capacity of selectivity measures the anti-oxidant potency of
different fractions in a complex makes the electro-chemical an innovative benchmark method. This is
an advantage in comparison to the spectrometric DPPH (2,2-diphenyl-1-picrylhydrazyl) stable assay,
which measures the anti-redox potential of the whole pool of compounds in an agent [43]. In addition,
the anti ROS effect of the oil was evaluated using GF and the biological MTT method, which is widely
applied to ascertain the capability of plant extracts to protect cells of different origins toward H2O2
stress [28,44]. Finally, the biocompatibility was assessed by means of WST-1 metabolic assay using
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four oral cell type lines. The assay allowed us to study the metabolic activity of each cell line after
contact with increasing concentrations of PLL-EO, as the viability of mammalian cells grown in culture
is largely applied as an indicator of potential toxic effects in animals [44]. In addition, considering that
any substance, particularly oral antimicrobials, may potentially come into direct contact with a wide
range of cells, we extensively conducted the safety assessment of PLL-EO by testing PDLF, GF, GK,
and DOK cells.
PLL is an evergreen environmentally-sustainable shrub, well adapted to harsh growing conditions,
dryness, and a warm environment, which all exercise an influence on the genotype [33]. PLL is rich in
alternate, leathery leaves, which represent the easiest means to extract the essential oil on a large scale.
Thus, the choice to use PLL-EO was aimed to produce highly-repeatable results in view of further
researches pointing to novel therapeutic formulations of the oil.
As it has been shown by the GC-MS, the PLL-EO has a high content of terpenes. The most
significant fractions were α-pinene and terpinen-4-ol constituting 33.38% of the total EO; furthermore,
limonene (3.89%) and β-myrcene (0.87%); (Z)-caryophyllene (1.39%) and (E)-caryophyllene (0.07%) were
detected (Table 1). These natural compounds are a matter of increasing interest in investigations [31,32]
and were recovered in the raw EO in a concentration above 0.05%, which allows us to classify PLL-EO
as pharmacologically-active [31]. The chemical composition of PLL-EO depends on the geographical
region. Our PLL-EO was high in α-pinene and sabinene content when comparing with PLL-EO
collected in Turkey [45] or even in other regions of Sardinia [35]. Both α-pinene and sabinene were
described to exert strong antibacterial activity [46,47], and additionally, α-pinene protects cells against
oxidative stress [48]. Comparing the chemical profile of the raw EO with that was reported in a previous
analysis regarding PLL leaves-EO from Sardinian biodiversity [33], it can be noted that, over time,
and regardless of harvesting and seasons, the concentration of such terpenoids has never been lower
than 0.05%. Consequently, our data attest to a fairly constant chemical profile of PLL leaves-EO.
The EO exerted antimicrobial activity against all the tested microorganisms (Table 2). It is
interesting to note that its activity was higher when compared to that reported in regard to isolated
fractions of the oil derived from plants growing in other Mediterranean areas [49,50]. This result can
suggest a synergy existing between the pharmacological fractions of terpenes, which characterize the
chemotype of PLL-EO we have assessed. High antibacterial activity was found against the reference
strains and clinical isolates of P. gingivalis and T. forsythia (MICs 1.63–3.13 µg/mL). Moreover, the oil
exerted activity toward other important species, e.g., F. nucleatum, which is a co-aggregating bacterium
in oral biofilms [51], further releasing bone-resorbing pro-inflammatory cytokines and chemokines [10],
and to a less extent, toward the commensal S. gordonii. This antimicrobial activity would allow the
possible use of PLL to antagonize gingivitis as a primary strategy to prevent periodontitis and a
secondary preventive strategy to recurrent periodontitis after periodontal surgery [3].
The possibility to formulate PLL-EO as a potential therapeutic or antiseptic is attractive as testing
the viability of GF by the MTT assay, it increased in the presence of the EO in comparison to that
observed in the control and DMSO (Figure 4). This evidence can indicate a possible revitalizing
ability of the oil toward oral fibroblasts. Our findings are emphasized by the fact that WST-1 did
not demonstrate cytotoxicity toward any of the evaluated cell cultures (Figure 5). A safe behavior of
PDLF moreover strengthens the use of PLL-EO as an antimicrobial in periodontal disease without
interferences in the immune and reparative events, in which fibroblasts are actively involved during the
infection [1,10]. Additionally, the biocompatibility with PDLF and GF may put extra emphasis on the
capacity of the oil in wound healing because these fibroblasts, as mesenchymal cells, perform important
vital functions and are responsible for much of the synthesis of new extracellular matrix during the
reparative procedures [1,10]. In regard to the biocompatibility with GK and DOK, it highlights PLL
as an antimicrobial with respect for stem cell differentiation and any stimulus toward dysplastic or
pre-malignant oral mucosa cells. All these results are appealing, especially because more and more
reports have evidenced that synthetic antimicrobials in several oral antiseptics possess cytotoxic effects
and suppress the viability of oral cells [19–21].
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We further demonstrated that the PLL-EO was capable of lowering the activity of COX-2 and LOX
enzymes (Figures 1 and 2), which are specifically produced in the course of an active inflammatory
process [11,12], like that which is developed during the periodontal infection [1,10]. Our in vitro data
is supported by in vivo studies that reported PLL-EO reduced the expression of COX-2 in experimental
rats, thus preventing harmful effects connected to eicosanoids accumulation in injury [35].
While the study reported here can suggest that PLL-EO could be considered as a useful
phytocomplex to treat causes and effects characterizing the periodontal disease, and in regard for oral
cells biocompatibility, the antioxidant activity which resulted was low (Figures 3 and 4). This data
seems not to be in accordance with previous reports [33,35,44], which measured the anti-ROS capacity
of PLL growing in Sardinia using the DPPH spectrophotometric assay and tested the antioxidant
protection of different types of PLL extracts on different cell lines in comparison to those used in the
present research. Chemically, disagreement can be explained through the different principles that
regulate the measurement of the total quantity of antioxidant molecules: the redox properties of
phenolics adopted by the electro-chemical method, and the ability of phenolics to scavenge the radical
by the DPPH assay [38]. In addition, the simultaneous measurement of the anti-redox potency of the
whole pool of compounds in an agent by the DPPH can lead to overestimation of the antioxidant
activity of individual chemical classes [43]. With regard to the antioxidant protection of PLL-EO toward
H2O2 damages in cell cultures, the replay could be different in in vivo experimentations and under
different testing conditions [44]. This assumption is supported by the fact that PLL-EO was capable of
reducing oxidation in frontal cortex cells of adult Wistar rats submitted to carotid artery obstruction [35].
Thus, this aspect should be further defined in future in vivo and in silico assessments.
Furthermore, PLL-EO evidenced antimicrobial activity against reference strains and clinical
isolates of C. albicans and C. glabrata (Table 2). The MIC values of PLL-EO were low against Candida sp.,
particularly in the case of C. glabrata, which is known for its clinical resistance to antimicrobials [52].
In fact, Candida tends to withstand anti-fungal treatments, especially when biofilms are formed. This is
probably due to the ability of the yeast to produce a high quantity of fungal PGE2, which also exhibits
cross-reactivity with that of the host [9]. The issues are increased because of the side effects of antifungal
therapies in humans, which may occur due to the poor ability of the drugs to target selectively the fungal
cell [9]. In an attempt to solve the problems connected to the yeast resistance, it was demonstrated
that the use of aspirin and other COX inhibitors (i.e., NADPHs), increased the anti-fungal efficacy of
some compounds, particularly against biofilm cells [53]. Results suggest that COX-2 inhibitors are
able to antagonize the biofilm development, resistance, and invasion of the yeast by lowering the level
of PGE2. In a similar way, LOX inhibitors showed activity toward fungal PGE2 in a dose-dependent
manner [9]. The finding reported here about PLL-EO inhibitory activity toward COX-2 and LOX may
be indicative of its capacity to regulate the aggressiveness of Candida sp. Thus, even if further studies
are needed to evaluate the specific activity of the EO towards biofilm development, the low MIC values,
in addition to the evidenced impact on the most important inflammatory mediators, should indicate
PLL-EO as a good antifungal agent, which acts directly against the yeast and indirectly against its
virulence with no oral cytotoxicity. This point will be a matter of our future researches.
4. Materials and Methods
4.1. Chemicals and Abbreviations
Thiazolyl blue tetrazolium bromide (MTT); isopropanol; streptomycin/penicillin; hydrogen
peroxide (H2O2); gentamicin; phosphate-buffered saline (PBS) were obtained from Sigma-Aldrich
(Milan, Italy). Dulbecco’s modified Eagle’s medium (DMEM) and Fetal Bovine Serum (FBS) were
purchased from Euroclone S.p.A. (Pero, Milan); dimethyl sulfoxide (DMSO).
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4.2. Plant Material, Essential Oil Extraction, and GC/MS Characterization
In October 2017, Pistacia lentiscus leaves (PLL) were harvested from wild plants growing on
an acidic-siliceous soil under typical Mediterranean climate conditions (Costa Paradiso-Sardinia,
41◦−3′−21′′ N, 8◦−57′−14′′ E). October was chosen because harvesting at this time of the year allows
attaining the highest amount of young-mature metabolic active leaves, before the winter senescence
takes place. The collected leaves were immediately cold stored (8 ◦C), transported to the laboratory,
and processed within 24 h. Before extraction, 3-uniform replicates of the leaves were prepared. Then,
a 4 h-hydro-distillation took place by a Clevenger-type apparatus, as the method of chose to obtain
the EO [54]. Following water removal, the recovered oil fraction termed ‘essential oil’ (PLL-EO) was
stored at −20 ◦C until analyses.
4.3. Gas Chromatography -Mass Spectrometry (GC-MS) Analysis
Replicates of the PLL-EO were separately analyzed using a GC (Hewlett-Packard Model 5890A)
equipped with a flame ionization detector and fitted with a 60 m × 0.25 mm, thickness 0.25 mm ZB-5
fused silica capillary column (Phenomenex). The injection port and detector temperature were 280 ◦C.
The column temperature was subjected to a linear rise (5 ◦C/min) starting from 50 ◦C with 3 halts: 1 min
at 135 ◦C; 5 min at 225 ◦C and a final 10 min halt at 260 ◦C. Oil samples of 0.2 µL (injection volume) were
analyzed, diluted in hexane using 2,6-dimethylphenol as an internal standard. Injection was performed
using a split/splitless automatic injector HP 7673 and helium as a carrier gas. Several measurements of
peak areas were performed through a HP workstation with a threshold set to 0.00 and peak width to
0.02. Compound quantification was expressed as absolute weight percentage using internal standard
response factors (RFs). Since oxygenated compounds have lower detectability than hydrocarbons by
the Flame Ionization Detector (FID), detector RFs were determined for key components relative to
2,6-dimethylphenol and assigned to other components on the basis of the functional group and/or
structural similarity. For this reason, we have multiplied the obtained data for the following correction
factors: hydrocarbons by 1; aldehydes and ketones by 1.24; alcohols by 1.28 and esters by 1.408.
GC-MS analysis was carried out with an Agilent Technologies model 7820A connected to a MS
detector 5977E MSD (Agilent) using the same column and operative conditions described formerly.
The column was connected with the ion source of the mass spectrometer. Mass units were monitored
from 10 to 900 AMU at 70 eV. The identification procedure was carried out exclusively considering
peaks ranging from 40 to 900 AMU. Compound identification was based on Rt values and mass spectra
comparison with those obtained from authentic samples and/or NIST and Wiley library spectra, or the
interpretation of EI-fragmentation of molecules [55].
4.4. Minimal Inhibitory Concentration Assay
According to the recommendations of EUCAST, the microbroth dilution technique was used to
measure the minimal inhibitory concentration. The inhibitory activity of PPL-EO was tested against
Streptococcus gordonii (ATCC 10558); Actinomyces naeslundii (ATCC 12104); F. nucleatum (ATCC 25586);
P. gingivalis (ATCC 33277 and two clinical isolates); T. forsythia (ATCC 43330 and two clinical isolates);
C. albicans (ATCC 76615 and two clinical isolates) and C. glabrata (DSM 6425 and two clinical isolates).
In short, PLL-EO was added in a two-fold dilution series beginning from 200 µg/mL. As culture
media, Wilkins-Chalgren broth was employed for all bacterial strains except for S. gordonii cultured
in an adjusted Mueller-Hinton broth. For Candida sp. the RPMI-medium was used. According to
EUCAST, after 18 h of incubation at optimal growing conditions, MIC was determined visually as the
lowest effective concentration of PLL-EO without microbial development. Experiments were made in
independent replicates (n = 3). A growth control containing distilled water instead of PLL-EO was
also included.
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4.5. Anti-Inflammatory Assays
4.5.1. COX-1/2 Inhibition
To determine the anti-inflammatory activity of 1.0, 10.0, or 100 µg/mL PLL-EO, an enzymatic
cell-free in vitro assay using human recombinant cyclooxygenase (COX-1, COX-2) (Sigma-Aldrich;
Prague, Czech Republic) was performed [27]. The activity was expressed as the percentage of
cyclooxygenase inhibition by PLL-EO compared to untreated samples (0.0 µg/mL PLL-EO). Briefly,
COX-1 (1 unit/reaction) or COX-2 (0.2 unit/reaction) was added to 180 µL of the incubation mixture
(100 mM Tris buffer pH 8.0; 5 µM porcine hematin; 18 mM L-epinephrine; 50 µM Na2EDTA) in a
96-well plate. PLL-EO (1.0, 10.0, and 100 µg/mL) was dissolved in ethanol (10 µL) and the reaction
was started with 10 µM arachidonic acid. Ibuprofen (1.0, 10.0, or 100 µg/mL) was used as the positive
control. The reaction was stopped after 20 min by adding formic acid (10%). The main product of this
reaction, PGE2, was quantified using a PGE2 ELISA kit according to the manufacturer’s instructions
(Enzo Life Sciences, New York, NY, USA). The absorbance was recorded at 405 nm (Tecan Infinite M200
microplate reader). Experiments were repeated three times with three technical replicates.
4.5.2. LOX Inhibition
An enzymatic cell-free in vitro assay using soybean LOX (Sigma-Aldrich; Prague, Czech Republic)
was carried out to test the inhibitory activity of 1.0, 10.0, 50.0, and 100 µg/mL PLL-EO [27]. The activity
was expressed as the percentage of inhibition compared to the untreated samples (0.0 µg/mL PLL-EO).
Briefly, the reaction mixture in a 96-well plate was made of LOX (0.8 units); 0.2 M borate buffer pH 8.5
(190 µL); PLL-EO (1.0–100 µg/mL) dissolved in ethanol, and linoleic acid (90 µM) was added as enzyme
substrate to start the reaction. Phenidone (1.0, 10.0, 50.0 and 100 µg/mL) was used as the positive
control. The inhibitory activity of PLL-EO on LOX was assessed by recording the absorbance of the
conjugated diene formed from linoleic acid at 234 nm (Tecan Infinite M200 microplate reader).
4.5.3. Antioxidant Activity
The electro-chemical characterization of PLL-EO was performed according to Barberis et al.
2010 [42] with some modifications, using a four-channel system (eDaQ Quadstat, e-Corder 410 and
Echem software, eDAQ Europe Poland) and screen-printed sensors (Metrohm Italiana s.r.l.) consisting
of a 4 mm working electrode (WE), an Ag/AgCl reference electrode (Ref) and a carbon counter electrode.
Air-bubbled PBS at pH = 7.4 was used as a supporting electrolyte. Voltammograms were obtained
placing a drop of 70 µL solution on the sensor surface. Cyclic voltammetries (CV), carried out in order
to investigate the PLL EO electro-chemical behavior at the WE surface vs. the Ag/AgCl Ref, were
executed starting from −200 mV to +800 mV, at a scan rate of 100 mV, in the absence (PBS + 1% DMSO)
and in the presence of PLL-EO and α-tocopherol, as the reference antioxidant compound. In order
to have a 200 mg/mL oil concentration, a solution of PLL-EO was prepared in PBS containing 1%
DMSO. In addition, CVs of α-pinene, terpinen-4-ol and α-phellandrene standards (Sigma-Aldrich,
Milan, Italy), as the three main represented compounds in the EO, were carried out using the same
methodology starting from −1 V to +1 V.
4.6. Viability Assay
4.6.1. Cell origin, Culture, and Treatments
The research was ethically conducted in accordance with the Declaration of Helsinki. The protocol
and informed consent forms were approved by the Ethics Committee at the University of Sassari
[n◦ 1000/CE] [56]. Gingival tissues were attained from donors subjected to wisdom teeth surgery at the
Department of Surgery of the Dental Unite, University of Sassari, Italy. Donors were healthy subjects,
not suffering from periodontitis or other chronic diseases. Patients were carefully informed of the
study’s purpose, risks, and benefits. Informed consent was obtained from all subjects prior to the study.
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Gingival primary fibroblasts were isolated from the above-mentioned gingival tissue. GF were cultured
in Dulbecco’s modified Eagle’s medium containing 10% FBS and 1% penicillin (100 U)/streptomycin
(100 µg/mL) at 37 ◦C under humidified 5% CO2/air. Then, 2 × 103 GF/100 µL (2nd–4th passage) were
plated in 96-well plates and amended with increasing concentrations of PLL-EO (0.0, 10, 25, 50, 75
and 100 µg/mL) dissolved in 0.1% DMSO. Immediately, plates were returned to the incubator for 24 h.
At this time, 100 µM H2O2 was added and the viability was determined by the MTT assay after 140 min.
The post-oxidative stress recovery effect of PLL-EO was checked using the same experimental plan
with the exception that GF cells were kept first amended with 100 µM H2O2 for 24 h, and then treated
with PLL-EO at the given concentrations before performing the MTT assay after 140 min.
4.6.2. MTT Assay
GF viability was evaluated by the MTT reduction assay [57]. In short, GF cells were incubated
with 100 µL (0.05 mg) of MTT for 3 h at 37 ◦C. Then, MTT was removed, and the precipitated blue
formazan crystals were dissolved in 100 µL of isopropanol and the color was read at 570 nm using
a microplate reader (EMax® Plus, Molecular Devices). Cell growth was calculated by normalizing
the absorbance of treated cells to the corresponding control. All the experiments were performed in
quadruplicate and repeated at least three times.
4.7. Cytotoxicity Assay
The WST-1 metabolic activity assay was conducted using PDLF (ScienCell Research Laboratories,
Carlsbad, CA, USA, Cat. No. 2620), GF (ScienCell, Cat. No. 2630), GK (The European Collection of
Authenticated Cell Cultures – ECACC, Cat. No. PCS-200-014), and DOK (ECACC, Cat. No. 94122104)
cells. All cells were seeded in 96-well plates (6 × 103 cells/well) employing DMEM with 10%
heat-inactivated FBS. After 24 h, the culture medium was replaced by the same medium amended
by increasing concentrations of PLL-EO (1.0, 10, 25, 50, 75, and 100 µg/mL) dissolved in DMSO
(0.1%) and ethanol. Control wells were supplemented by the sole medium with 0.1% DMSO and
ethanol. After 24 h of exposure, the medium was removed, and the cells were rinsed twice with
150 µL PBS. Then, according to the manufacturer’s instructions, 100 µL of culture medium without
FBS containing 0.3 mg/mL cell proliferation reagent WST-1 (Roche, Sigma-Aldrich) was added to each
well. Absorbance was measured immediately at 450/650 nm (Tecan Infinite M200 microplate reader)
and repeated after 2 h. Metabolic activity of each cell line was assayed in six parallels and in three
independent experiments. Viability of the treated cells was expressed as a percentage referred to
untreated controls (viability 100%). The calculations were done using GraphPad Prism 8.1.0 (GraphPad
Software, San Diego, CA, USA).
5. Conclusions
Herein, we documented the antimicrobial capacity of PLL-EO, which exhibits a broad-spectrum
activity against periodontal bacteria and Candida as reference strains and clinical sp., antagonizing
them with low MICs. Furthermore, our in vitro study reported that PLL-EO has inhibitory activity
toward arachidonic acid oxidative enzymes, specifically proposing the oil as an interesting dual
inhibitory agent against COX-2 and LOX. Data suggest a possible role of the EO in the resolution of the
inflammatory process, which accompanies periodontal and Candida infections. These facts also sustain
that PLL-EO could be a novel antifungal agent that acts directly against the yeast and indirectly against
its virulence. All the above-mentioned considerations, further supported by the wide biocompatibility
in oral cells, validate our hypothesis and underline the potential of PLL-EO obtained from leaves
collected at Costa Paradiso-Sardinia, as an ingredient in oral health-care products for the long-term use.
Such oral-health care products may have beneficial effects in periodontal therapy, as they may prevent
gingival inflammation and Candida infections, in particular in immune-compromised patients.
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